What question did this study set out to answer?

To examine the regulatory evolution, evaluation challenges, and clinical outcomes of genetically engineered adoptive cell therapies reviewed for orphan designation by the European Medicines Agency over a 10-year period.

March 14, 2024Gene TherapyOpen Access

Advancing rare disease treatment: EMA’s decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation

View Full Paper

Ask AI

Bookmark

Authors

MKMaria Elisabeth KallandEuropean Medicines Agency TPTomás Pose‐BoirazianUniversidade de Santiago de Compostela GPGloria M. PalomoEuropean Medicines Agency

Discussion

Member takes

Implication

Regulatory landscape analysis reveals high approval and maintenance rates for CAR-T cell therapies in rare cancers, highlighting the crucial role of early clinical benefit data.

Key Points

To examine the regulatory evolution, evaluation challenges, and clinical outcomes of genetically engineered adoptive cell therapies reviewed for orphan designation by the European Medicines Agency over a 10-year period.
Analyzed 36 applications evaluated for orphan designation and status maintenance by the EMA's Committee for Orphan Medicinal Products.
Assessed product characteristics, including cell type origin and vector platforms, predominantly in rare haematological B-cell malignancies.
Orphan designation was granted to 30 of 36 applications, and 89% (32/36) established significant benefit based on clinically relevant advantages over existing treatments.
Preliminary clinical data supported 80% (29/36) of submissions at initial orphan designation.
Significant benefit over existing therapies was maintained in 12 of 14 applications reviewed at marketing authorisation or indication extension, with one application withdrawn during evaluation.

Cite This Study

Kalland et al. (2024) studied this question.

synapsesocial.com/papers/6a70a9e7f44fa9f079de57b0 https://doi.org/10.1038/s41434-024-00446-0

View Full Paper

Ask AI

Bookmark

Implication

Regulatory landscape analysis reveals high approval and maintenance rates for CAR-T cell therapies in rare cancers, highlighting the crucial role of early clinical benefit data.

Advancing rare disease treatment: EMA’s decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation

Discussion

Member takes

Implication

Key Points

Cite This Study

Advancing rare disease treatment: EMA’s decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider